基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線DLBCL的臨牀試驗申請
格隆匯3月6日丨基石藥業-B(02616.HK)發佈公吿,公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。
本次Ib期臨牀試驗在CS5001單藥治療後線侵襲性和惰性晚期淋巴瘤的數據基礎上進一步拓展,旨在深入探索ROR1 ADC在DLBCL全病程的臨牀應用價值,並持續拓展實體瘤治療。試驗拓展部份設計包括:聯合R-CHOP:治療既往未接受過全身系統性治療的DLBCL患者;聯合二線標準療法:治療復發或難治DLBCL患者;單藥:治療ROR1表達陽性的晚期實體瘤患者;聯合舒格利單抗:治療晚期實體瘤患者。
基石藥業首席執行官、研發總裁及執行董事楊建新博士表示:“我們非常高興看到CS5001(ROR1 ADC)的臨牀開發取得這一重要進展。現有數據已充分表明,CS5001在實體瘤與淋巴瘤治療領域均展現出極為廣闊的應用潛力。在一項II期臨牀研究中,ROR1 ADC聯合R-CHP方案在一線DLBCL治療中已取得了令人矚目的完全緩解(CR)率。隨着我們的Ib期臨牀試驗從後線單藥療法進一步拓展至前線治療DLBCL的聯用療法,CS5001有望為DLBCL患者帶來突破性的治療獲益,並重塑該疾病的標準治療格局。此外,作為首個已知在實體瘤和淋巴瘤中均觀察到臨牀抗腫瘤活性的ROR1 ADC,我們也在積極推進CS5001針對實體瘤的探索,對其後續的臨牀表現充滿期待。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.